We're conducting crucial studies to secure EU drug registration, paving the way for phase 1 clinical trials on healthy volunteers. Our collaboration involves five top labs across Poland and Slovakia. We've already applied for funding from a Polish state agency, potentially covering 80% of our capital needs from public funds. We seek investors to match the remaining 20%. For further details, please reach out via the contact form below.

At present, IBS remains incurable, impacting patients' quality of life with symptoms like abdominal pain, cramping, bloating, constipation, and diarrhea. Existing over-the-counter options offer limited or short-term relief, while prescribed medications are costly and have adverse effects, often targeting only one symptom. Our new drug aims to offer a much-needed solution, potentially benefiting 10% to 20% of the global population affected by this discomforting disease.

Our firm was set up as a joint venture of an American Green Space Labs Inc., Medi Ventures sp. z o.o., a Polish venture capital arm of Chicago Poland Ventures and a private individual from Poland.

Our international team of experts from Poland, UK and USA ensures professional and ethical conduct aimed at obtaining the most reliable and valuable data for further phases 2 and 3 studies.